A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Brief description of study

If you have been diagnosed with mantle cell lymphoma that has relapsed or refractory (lymphoma that has either come back or progressed on treatment), you may qualify for this Phase I/II study. The main goal of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.


Clinical Study Identifier: s17-00793
ClinicalTrials.gov Identifier: NCT03323151
Principal Investigator: Catherine M Diefenbach
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.